Clinical application of parenteral nutrition in the treatment of five ponies and one donkey with hyperlipaemia.

The research details the use of lipid-free partial parenteral nutrition in managing hyperlipaemia in horses and donkeys, with promising results despite some complications.

Study Design and Subject Selection

• The study focused on the treatment of hyperlipaemia, a disease causing high levels of circulating lipids, in equids: specifically, five ponies and one donkey.
• These animals cared for different primary clinical conditions, but all suffered from secondary hyperlipaemia.

Treatment Method

• Researchers applied lipid-free partial parenteral nutrition (PPN) to the subjects. This treatment bypasses the digestive system and delivers nutrients directly into the blood.
• The PPN mixture used contained 50% glucose and 15% amino acids in equal volumes, supplying energy and protein at specific rates.

Outcomes and Findings

• All six animals responded positively to the treatment, showing a quick and maintained decrease in serum concentrations of triglyceride, a type of blood fat linked to hyperlipaemia.
• In four of the cases, the primary health condition improved considerably, and these animals were successfully discharged.
• The remaining two did not show significant improvement in their primary condition, leading to their euthanasia. However, their hyperlipaemia was effectively resolved.

Complications

• The principal complication following parenteral nutrition was hyperglycaemia, an excessively high level of glucose in the blood, presumably due to the significant glucose component in the PPN.

Conclusions and Influence on Future Study

• The study presents a promising tactic for managing hyperlipaemia involving lipid-free partial parenteral nutrition offering rapid and sustained reduction of hyperlipaemia conditions in equids.
• Future studies may focus on addressing complications, such as hyperglycaemia, and in refining the treatment method to improve responses in other health issues that equids face.